WO2007150049A3 - Lactoferrin as a radioprotective agent - Google Patents

Lactoferrin as a radioprotective agent Download PDF

Info

Publication number
WO2007150049A3
WO2007150049A3 PCT/US2007/071942 US2007071942W WO2007150049A3 WO 2007150049 A3 WO2007150049 A3 WO 2007150049A3 US 2007071942 W US2007071942 W US 2007071942W WO 2007150049 A3 WO2007150049 A3 WO 2007150049A3
Authority
WO
WIPO (PCT)
Prior art keywords
lactoferrin
combination
damaging
irradiation
radioprotective agent
Prior art date
Application number
PCT/US2007/071942
Other languages
French (fr)
Other versions
WO2007150049A2 (en
Inventor
Atul Varadhachary
Karel Petrak
Paul Blezinger
Original Assignee
Agennix Inc
Atul Varadhachary
Karel Petrak
Paul Blezinger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Inc, Atul Varadhachary, Karel Petrak, Paul Blezinger filed Critical Agennix Inc
Priority to US12/305,944 priority Critical patent/US20100215699A1/en
Priority to CA002655331A priority patent/CA2655331A1/en
Priority to EP07784522A priority patent/EP2049135A4/en
Publication of WO2007150049A2 publication Critical patent/WO2007150049A2/en
Publication of WO2007150049A3 publication Critical patent/WO2007150049A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This present invention relates to the field of protecting against, or rectifying the effects of damaging ionizing irradiation. The method of treatment involves oral administration of a lactoferrin composition, alone or in combination with other treatments, both in combination with other radio-protective agents and/or the standard of care. Further, the method of treatment provides for a topical administration of lactoferrin to treat lesions caused by local damaging irradiation.
PCT/US2007/071942 2006-06-22 2007-06-22 Lactoferrin as a radioprotective agent WO2007150049A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/305,944 US20100215699A1 (en) 2007-03-07 2007-06-22 Lactoferrin as a radioprotective agent
CA002655331A CA2655331A1 (en) 2006-06-22 2007-06-22 Lactoferrin as a radioprotective agent
EP07784522A EP2049135A4 (en) 2006-06-22 2007-06-22 Lactoferrin as a radioprotective agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80554006P 2006-06-22 2006-06-22
US60/805,540 2006-06-22

Publications (2)

Publication Number Publication Date
WO2007150049A2 WO2007150049A2 (en) 2007-12-27
WO2007150049A3 true WO2007150049A3 (en) 2008-02-21

Family

ID=38834430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/071942 WO2007150049A2 (en) 2006-06-22 2007-06-22 Lactoferrin as a radioprotective agent

Country Status (4)

Country Link
EP (1) EP2049135A4 (en)
CN (1) CN101505781A (en)
CA (1) CA2655331A1 (en)
WO (1) WO2007150049A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201304041D0 (en) 2013-03-06 2013-04-17 Water Jel Europ Llp Treatment and prophylaxis of radiation dermatitis
CN111671885A (en) * 2020-06-15 2020-09-18 中国人民解放军西部战区总医院 Medicine for treating radiodermatitis
CN111514280A (en) * 2020-06-15 2020-08-11 中国人民解放军西部战区总医院 Medicine for preventing radiodermatitis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203839A1 (en) * 1999-10-29 2003-10-30 Kruzel Marian L. Immune enhancing composition containing lactoferrin
US20060094082A1 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Composition of lactoferrin related peptides and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571697A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5571691A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
DK0590060T3 (en) 1991-06-21 1998-05-11 Univ Cincinnati Orally administrable therapeutic proteins and method of preparation
ZA932568B (en) 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
AU6307698A (en) 1997-02-03 1998-08-25 Pharming Bv Useful properties of human lactoferrin and variants thereof
WO2001024812A1 (en) * 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
EP1258243A1 (en) * 2001-05-16 2002-11-20 N.V. Nutricia Lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy
EP1581066A1 (en) * 2003-01-07 2005-10-05 N.V. Nutricia A method of improving nutrient utilisation by a mammal and a composition for use therein
US20040214750A1 (en) * 2003-04-28 2004-10-28 Georgiades Izolda M. Medicaments for healing skin conditions in humans
RU2294755C1 (en) * 2005-06-21 2007-03-10 Федеральное государственное унитарное предприятие Государственный научный центр - Институт биофизики Федерального медико-биологического агентства Method for treating acute radiation disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203839A1 (en) * 1999-10-29 2003-10-30 Kruzel Marian L. Immune enhancing composition containing lactoferrin
US20060094082A1 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Composition of lactoferrin related peptides and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2049135A4 *

Also Published As

Publication number Publication date
EP2049135A4 (en) 2009-12-30
CA2655331A1 (en) 2007-12-27
WO2007150049A2 (en) 2007-12-27
EP2049135A2 (en) 2009-04-22
CN101505781A (en) 2009-08-12

Similar Documents

Publication Publication Date Title
WO2008098192A3 (en) Compositions and methods for treating neuropathy
WO2008122049A3 (en) Methods and compositions for reduction of side effects of therapeutic treatments
WO2010062581A3 (en) A botanical composition for enhanced skin repair and uses thereof
WO2009149369A3 (en) Acne treatment compositions comprising nanosilver and uses
HK1141231A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of migraine
WO2007096601A3 (en) Antimicrobial formulations comprising a quinone and a copper salt
WO2009039460A3 (en) Co-administration of pimavanserin with other agents
EP1880719A3 (en) Composition for prophylaxis or treatment of urinary system infection and method thereof
MX2010005012A (en) Compositions for the treatment and prevention of eyelid swelling.
HK1125039A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
WO2007127333A3 (en) Compositions for the treatment and prevention of eyelid swelling
WO2009079451A3 (en) Compositions and methods of promoting wound healing
WO2009158248A3 (en) Method and compositions for improving skin and body appearance
WO2008010991A3 (en) Methods and compositions for the treatment of cancer
IL186960A0 (en) Methods of suppressing uv light-induced skin carcinogenesis
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
WO2007084614A3 (en) Hair growth formula
WO2008042944A3 (en) Non-irritating oral care formulations
WO2010054083A3 (en) Inhalation formulation for treating and prophylatic use in bacteria, mycobacterial and fungal respiratory infections
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
HK1112721A1 (en) Tissue disruption treatment and composition for use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780030596.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07784522

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2655331

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 5/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007784522

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 12305944

Country of ref document: US